Healthcare Cancer Metabolism Based Therapeutics Market | Página 2

REPORT DESCRIPTION
Cancer Metabolism Based Therapeutics Market – Overview
Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer
compound - Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the
mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical
trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the
treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS).
Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt
lymphoma and T-cell lymphoma in near future. Therefore, offering orphan drug to the cancer patients
would help to gain more value and share for cancer metabolism based therapeutics market.
Celgene Corporation and Agios Pharmaceutical announced that the Food and Drug Administration (FDA)
approved New Drug Application (NDA) for enasidenib – oral form, in August 2017. The FDA granted the
NDA, as a priority review for cancer metabolism drug. Enasidenib is a first-in-class drug, which is
expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2
(IDH2) mutation.